Deals: Page 83
-
Novare Pharmaceuticals launches in Boston
The new biotech specializes in a type of tissue engineering that may have groundbreaking applications in treating inflammatory conditions and breast reconstruction.
By Nicole Gray • Oct. 8, 2014 -
Actavis shores up infectious disease franchise with Durata acquisition
With its $675 million buyout of Durata, Actavis is acquiring Dalvance (dalbavacin)—the very first FDA-designated qualified infection disease product (QIDP)—as part of the package.
By Nicole Gray • Oct. 7, 2014 -
Baxter invests $45M in Rockwell Medical
The capital infusion will shore up Rockwell's hemodialysis concentrates division and allow the smaller company to focus on growth and expansion.
By Nicole Gray • Oct. 6, 2014 -
Optos to collaborate with UK government and universities
The $16-million collaboration is intended to develop cutting-edge optical imaging technology.
By Nicole Gray • Oct. 6, 2014 -
Bayer a top OTC player after $14.2B deal with Merck
Bayer’s OTC division is larger than J&J’s as of October 1 thanks to its $14.2 billion acquisition of Merck’s consumer care division.
By Nicole Gray • Oct. 2, 2014 -
Acquisition update: J&J buys Alios for $1.75 billion
Alios Biopharma brings a portfolio of potential treatments for viral infections, including a drug in development for the treatment of respiratory syncytial virus (RSV).
By Nicole Gray • Oct. 1, 2014 -
Horizon hailed as 'world's leading gene-editing' company after acquiring Sage
Horizon is paying up to $48 million for Sage Labs, considered "a world leader in the generation of advanced in vivo transgenic disease models for use in preclinical research."
By Nicole Gray • Sept. 30, 2014 -
Amag Pharma buys maternal health specialist Lumara in $1B deal
Amag is paying $675 million for Lumara, bringing the well-known premature birth drug Makena into Amag's portfolio.
By Nicole Gray • Sept. 30, 2014 -
Acquisition update: Daiichi Sankyo buys Ambit Biosciences for $410 million
Daiichi is shoring up its oncology portfolio as it acquires Ambit’s late-stage acute myeloid leukemia drug, along with other cancer treatments.
By Nicole Gray • Sept. 30, 2014 -
Merger Monday: Pfizer snaps up Innopharma in $360M deal
Innopharma is an NJ-based pharma company that focuses on complex injectable delivery forms.
By Nicole Gray • Sept. 29, 2014 -
GSK names Royal Bank of Scotland head its next chairman
Sir Philip Hampton joins GlaxoSmithKline at a tumultuous time. Luckily for the company, he has some experience dealing with chaos.
By Sy Mukherjee • Sept. 25, 2014 -
Deep Dive
Collaborating with Chinese pharma: Inside one company's success story
CleveXel CEO Christian Bloy tells BioPharma Dive how his company cultivated collaborative relationships and leveraged its expertise in development and innovation to develop anti-malarials in China.
By Nicole Gray • Sept. 23, 2014 -
Tax-inversion hopefuls balk at new White House plans to curb deals
Companies whose tax-shifting mergers aren't finalized are nervous about the Obama admin's "first, targeted steps" to curb the increasingly popular deals.
By Sy Mukherjee • Sept. 23, 2014 -
Montgomery County Planning Commission
Merck KGaA buys lab supplies manufacturer in major $17 billion deal
Missouri-based Sigma-Aldrich is the largest supplier of biochemicals and organic chemicals to research laboratories.
By Nicole Gray • Sept. 23, 2014 -
Auxilium: Endo's $2.2B takeover bid 'significantly undervalues' company
But Auxilium stopped short of outright rejecting the offer.
By Sy Mukherjee • Sept. 22, 2014 -
Bayer to spin off material science division into separate company
Bayer says goodbye to its three-pillar business model as healthcare takes center stage.
By Nicole Gray • Sept. 19, 2014 -
Pfizer nabs exclusive option for MedGenesis Parkinson's treatment
MedGenesis has developed GDNF, a growth factor that supports brain cell survival and has promise for helping Parkinson's patients.
By Nicole Gray • Sept. 18, 2014 -
Denovo snaps up Lilly's failed cancer drug for undisclosed price
Lilly has ceded all commercialization rights of enzastaurin to Denovo after the investigational cancer treatment failed to meet primary endpoints in a phase III trial for treatment of lymphoma.
By Nicole Gray • Sept. 18, 2014 -
Endo bids $2.2 billion for Auxilium
Auxilium’s portfolio would be a nice addition to Endo’s core offerings -- but the former company's position isn't clear yet.
By Nicole Gray • Sept. 18, 2014 -
Deep Dive
ICYMI: How one Shanghai pharma became a model for malaria drug production
With half the world at risk for malaria, large-scale treatment production is crucial. Pharma companies in China and France are collaborating to make it happen.
By Nicole Gray • Sept. 18, 2014 -
AstraZeneca, Lilly plan sprint to Alzheimer's drug development
The team plans to rapidly move their new Alzheimer’s treatment into phase III development after promising phase I studies.
By Nicole Gray • Sept. 17, 2014 -
Recordati to market Plethora's premature ejaculation spray
Last fall, the EU approved UK-based Plethora’s spray for use five minutes before sexual intercourse to prevent premature ejaculation.
By Nicole Gray • Sept. 17, 2014 -
Gilead to allow Indian generics of pricey Sovaldi in developing nations
The deal covers 91 countries that contain more than half of the global infected population.
By Sy Mukherjee • Sept. 15, 2014 -
Google's Calico pens development deal for Parkinson's, ALS-fighting compound
The hot new kid on the pharma scene will set up labs in Dallas to produce UT Southwestern's P7C3 compounds.
By Sy Mukherjee • Sept. 11, 2014 -
Pfizer and Astellas Pharma to no longer co-distribute Caduet in Japan
The two companies, which have co-promoted/distributed the hypertension drug since 2009, are terminating the agreement early.
By Nicole Gray • Sept. 10, 2014
Previous
